Physician profile
Vincent Meng
NPI 1346925963
$16,247.12
in general payments reported to CMS, 2019-2025
24 companies · $9,543 in 2025
The $9,543 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $101 · 2024: $6,603 · 2025: $9,543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $3,880.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,367.12 |
| Consulting Fee | $3,880.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,741.54 | 2024-2025 | Sotyktu |
| Ucb, INC. | $1,588.20 | 2024-2025 | Bimzelx |
| Janssen Biotech, INC. | $1,364.71 | 2024-2025 | Tremfya, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $1,351.47 | 2024-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,347.18 | 2024-2025 | Cabtreo, Siliq, Duobrii |
| Dermavant Sciences, INC. | $1,280.15 | 2024 | Vtama |
| Abbvie INC. | $986.74 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $951.88 | 2024-2025 | Zoryve |
| Incyte Corporation | $896.02 | 2024-2025 | Opzelura, Opzelura |
| Galderma Laboratories, L.P. | $784.64 | 2024-2025 | Nemluvio, Dysport, Aklief |
| Leo Pharma INC. | $633.84 | 2024-2025 | Adbry |
| Amgen INC. | $447.45 | 2024-2025 | Otezla, Otezla |
| Lilly USA, LLC | $436.14 | 2024-2025 | Ebglyss, Olumiant, Taltz |
| Genzyme Corporation | $409.47 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $381.78 | 2024-2025 | Dupixent |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $313.13 | 2025 | Sofdra |
| Novartis Pharmaceuticals Corporation | $278.88 | 2025 | |
| Organon LLC | $228.22 | 2025 | Vtama |
| Edwards Lifesciences Corporation | $169.03 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Pfizer INC. | $167.97 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $145.13 | 2024 | Tremfya |
| Blueprint Medicines Corporation | $123.76 | 2025 | Ayvakit |
| Regeneron Pharmaceuticals, INC. | $120.17 | 2025 | Dupixent |
| Biofrontera INC. | $99.62 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Meng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.